Skip to main content
Equibles

ABVX · Abivax S.A.

Track ABVX — free

Use ABVX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABVX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$92.42 +0.69 (+0.75%)
Rebalance outlook locked
Market Cap
$8.14B
Shares
87.25M
Volume · Oct 5 840.31K Avg daily vol (3M) 1.09M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$91.73 Open$92.27 Day$89.40–92.61 52W close$72.50–145.31 Avg vol 30d1.2M Short int6.9M · 7.9% float · 6.2d Short vol38% Last earningsDec 14, 2026 DataOct 2023–Oct 2026

Up next

Next earnings call
Dec 14, 2026 Scheduled · in 10 wks
Q4 2023 earnings call transcript
call held Dec 31, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+12.1%
Trailing year
Short interest
7.9%
Latest settlement · 6.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −22%
below
Price vs 50-day avg −19%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −27%
trailing
YTD return −32%
this year
Relative strength −39%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $114 › 200d $118 — 200d above 50d
Institutional flow Distributing
2 of 308 funds reported for Sep 30 · net -38 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.86% of float · ▼ -1.5% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
308 holders — near 2-yr high, broad support
Squeeze score 51
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −50%
past year
ATR 5.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−22% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $114 › 200d $118 — 200d above 50d
Institutional flow Distributing
2 of 308 funds reported for Sep 30 · net -38 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.86% of float · ▼ -1.5% MoM · 6.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
308 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $73 Now $92 · 26% Range high $145
vs 200-day avg -22% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABVX
Abivax S.A.
this stock
$8.14B -32.0% — — 7.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
309
% held
76.3%
Reported
2 of 308
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
90
View
Short & Settlement
Short Interest Falling
Shares short
6.9M
Days to cover
6.2d
Change
-103.5K sh
View
Short Volume
Short vol %
38%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
3
Value
$341
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
48.2%
Week of
Aug 31, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 21, 2026
This year
11
View
Proposed Sales
Value
$133.7M
Shares
1.0M
Filed
Jan 8, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 14, 2026
Last webcast
Sep 21, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ABVX -5.3% -20.1% -27.1% -7.4% -32.0%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -6.5% -20.7% -38.7% -9.0% -45.6%
Key facts CIK 1956827 CUSIP 00370M103 13F (30d) 8 filings 8 filers Visit website Investor relations